YLR311C Antibody

What is the YLR311C antibody and what cellular targets does it recognize?

While the search results don't specifically describe a YLR311C antibody, we can draw parallels from similar research antibodies such as YU311. Monoclonal antibodies like YU311 have been generated against specific antigens expressed on cell surfaces, particularly in research involving resistant cell lines. YU311, for example, recognizes a 92-kDa membrane protein expressed on ara-C-resistant human leukemic cell lines but not on sensitive parental cell lines . This differential reactivity highlights the importance of identifying target specificity when working with research antibodies. When developing or selecting antibodies for research, confirmation of target binding through techniques such as Western blotting, immunoprecipitation, or immunocytochemistry is essential to verify specificity.

How are monoclonal antibodies against specific cellular targets generated?

Monoclonal antibodies against specific targets are typically generated through a systematic immunization and selection process. From the literature, we can see that researchers generate monoclonal antibodies by immunizing animals (commonly rats or mice) with purified target proteins or cells expressing the protein of interest . For instance, antibody 496 was raised in Sprague Dawley rats to human IL-17A . Following immunization, B cells are isolated and either fused with myeloma cells to create hybridomas or selected directly using single B cell selection methods . The resulting antibodies are then screened for specificity and functionality, such as the ability to inhibit target-induced cellular responses. Humanization of promising candidates often follows to reduce immunogenicity for potential therapeutic applications.

What methods are used to confirm antibody specificity?

Multiple complementary methods should be employed to confirm antibody specificity:

Researchers have used indirect ELISA to determine cross-reactivity of antibodies with related family members, as demonstrated with antibody 496.g1 binding to IL-17 family members . Additionally, functional assays like inhibition of IL-17-induced IL-6 production in cell lines have been used to verify both specificity and activity . When testing new antibodies, inclusion of appropriate controls (isotype-matched control antibodies, knockout cell lines) is essential for interpretation.

How can antibody engineering improve target specificity and affinity?

Antibody engineering represents a sophisticated approach to enhance functionality beyond what's achieved through traditional hybridoma methods. Using directed evolution and rational design strategies, researchers can significantly improve binding characteristics. For example, with antibody 496.g1, researchers used an in silico design method to identify five mutations in the light chain variable region that increased binding affinity for IL-17F while also improving affinity for IL-17A, creating the enhanced antibody 496.g3 . This resulted in remarkable improvements, with the affinity constant (KD) for IL-17F improving from 1510 pM to 35 pM (43-fold increase) and for IL-17A from 29 pM to 7 pM (4-fold increase) . When considering antibody engineering projects, researchers should establish clear affinity targets and employ multiple verification methods to confirm improvements.

What approaches can detect antigenic changes in resistant versus sensitive cell lines?

Identifying antigenic changes between drug-resistant and sensitive cell lines requires comprehensive comparative analysis. In studies with ara-C-resistant leukemic cells, researchers developed monoclonal antibodies like YU311 that specifically recognized resistant cell lines (KY-Ra) but not sensitive parental lines (KY-821) . This approach enabled identification of a 92-kDa membrane protein expressed exclusively in resistant cells . To investigate such antigenic differences:

• Generate antibodies using the resistant cell line as immunogen

• Screen for differential reactivity between resistant and sensitive lines

• Characterize the recognized antigen through immunoprecipitation and mass spectrometry

• Perform functional studies to determine if the identified antigen contributes to resistance

Interestingly, while major differentiation antigens remained stable between resistant and sensitive lines in immunocytochemistry, specific resistance-associated membrane proteins emerged, suggesting targeted antigenic changes rather than global alterations .

How can dual-targeting antibodies be developed for related protein targets?

Developing antibodies capable of neutralizing multiple related proteins presents unique challenges but offers potential advantages in research and therapeutic applications. The development of bimekizumab (antibody 496.g3) demonstrates a successful approach to creating a dual-targeting antibody against IL-17A and IL-17F . The process involved:

• Initial generation of an antibody with primary specificity for one target (IL-17A)

• Discovery of weak cross-reactivity with the second target (IL-17F)

• Strategic mutation of the light chain variable region to enhance affinity for the secondary target while maintaining or improving affinity for the primary target

• Functional validation showing improved neutralization of both targets

This approach resulted in an antibody with IC90 values of 0.02 nM against IL-17A and 23.41 nM against IL-17F, representing a 10-fold improvement in potency against IL-17F compared to the parent antibody . When designing dual-targeting antibodies, researchers should carefully evaluate binding epitopes and potential allosteric effects to ensure simultaneous binding capability.

What functional assays best validate antibody activity in research applications?

Functional validation is critical to confirm that an antibody not only binds its target but also modulates its biological activity. Effective functional assays should:

• Measure physiologically relevant endpoints

• Include appropriate positive and negative controls

• Demonstrate dose-dependent effects

• Account for potential off-target activities

For example, researchers validated antibody YU311 through growth inhibition assays on KY-Ra cells both with and without ara-C, demonstrating functional impact beyond simple binding . Similarly, for IL-17-targeting antibodies, researchers measured inhibition of IL-17-induced IL-6 production in normal human dermal fibroblasts (NHDFs) . When TNF and IL-17 were combined to produce synergistic stimulation, both 496.g1 and 496.g3 antibodies inhibited IL-17A and IL-17F activity, reducing stimulation to the level seen with TNF alone . This approach demonstrated specificity and provided quantitative IC90 values for comparative analysis.

How should researchers design experiments to characterize newly identified membrane proteins recognized by research antibodies?

Characterizing novel membrane proteins recognized by research antibodies requires a systematic experimental approach:

In the case of the 92-kDa membrane protein recognized by YU311, researchers established its role in regulating cell growth by demonstrating that the antibody inhibited growth of KY-Ra cells . This suggests the protein may be functionally involved in sustaining proliferation of resistant cells. When designing such experiments, researchers should include appropriate controls and consider multiple methodological approaches to build a comprehensive understanding of the protein's biological role.

What considerations are important when using antibodies to detect CAR-engineered cells?

Detection of chimeric antigen receptor (CAR)-engineered cells presents unique challenges that require specialized antibody approaches. Rather than detecting the variable regions that differ between CARs, researchers have developed antibodies targeting constant elements like the linker sequences between variable domains. Anti-CAR linker recombinant monoclonal antibodies bind to either G4S or Whitlow/218 linker sequences between the variable heavy and variable light domains of scFv-based CARs . This approach offers several advantages:

• Universal detection regardless of CAR antigen specificity

• Compatibility with various experimental applications (flow cytometry, immunohistochemistry)

• Utility in multiple research workflows (detection, analysis, quantitation, purification)

When using such antibodies, researchers should validate their specificity against non-transduced control cells and consider potential epitope masking due to protein folding or interactions with other cell surface molecules .

How can researchers address apparent contradictions between antibody binding and functional assays?

Discrepancies between binding and functional data can arise from multiple sources and require systematic investigation:

• Epitope accessibility: An antibody may bind its target in binding assays but fail to neutralize function if the binding epitope differs from the functional domain. Epitope mapping can help resolve such discrepancies.

• Antibody concentration effects: Binding may occur at concentrations insufficient for functional neutralization. Compare EC50 values from binding assays with IC50 values from functional assays.

• Target context differences: The target protein may exist in different conformations or complexes in various assay systems. For example, when evaluating 496.g3 against IL-17F, researchers observed that neutralization required higher antibody concentrations when the ratio of IL-17F to IL-17A increased .

• Compensatory pathways: In cellular assays, alternative signaling pathways may compensate for antibody-mediated inhibition of the primary target.

To systematically address such contradictions, researchers should perform dose-response studies, examine temporal aspects of binding versus functional inhibition, and consider additional controls such as known neutralizing antibodies.

What pharmacokinetic models help predict antibody efficacy in complex biological environments?

Sophisticated modeling approaches can bridge the gap between in vitro characterization and in vivo performance expectations. Target-mediated drug disposition (TMDD) models have proven valuable for predicting antibody-target interactions in different tissues. For antibody 496.g1, researchers used a TMDD model to predict the percentage of IL-17A or IL-17F bound to the antibody in skin . These simulations predicted that following a 160 mg IV dose every 4 weeks, IL-17A would be completely bound in plasma and >95% bound in skin at trough, but IL-17F would show <50% occupancy at the same timepoint .

Key considerations for pharmacokinetic modeling include:

• Allometric scaling to predict pharmacokinetic parameters in humans

• Tissue partitioning estimates (e.g., 30% of antibody partitioning to skin was assumed)

• Target expression levels in different tissues

• Antibody affinity constants determined through surface plasmon resonance or similar techniques

These models can inform experimental design by helping researchers determine appropriate dosing for preclinical studies and identifying potential limitations in target coverage that might necessitate antibody engineering for improved affinity.

How should researchers interpret changes in antigen expression between drug-resistant and sensitive cell lines?

Interpreting antigenic changes in drug-resistant cell lines requires careful consideration of multiple factors:

• Direct resistance mechanism: Determine if the identified antigen directly contributes to drug resistance (e.g., through drug efflux, metabolism, or altered drug target).

• Compensatory adaptation: The antigen may represent a compensatory change that supports survival under drug pressure without directly mediating resistance.

• Clonal selection: Drug-resistant populations may emerge from pre-existing resistant subclones rather than de novo adaptation.

• Stability of changes: Assess whether antigenic changes persist in the absence of drug pressure.

In the case of the YU311-recognized antigen in ara-C-resistant cells, researchers noted that expression of usual differentiation antigens remained stable between resistant and sensitive lines despite emergence of the 92-kDa protein . This suggests that the antigenic change represents a specific adaptation rather than general dedifferentiation or phenotypic drift. Additionally, the finding that YU311 inhibited growth of resistant cells implicates the recognized protein in cellular proliferation, potentially explaining its role in the resistant phenotype .

How might single-cell analysis enhance antibody-based detection of heterogeneous cell populations?

Single-cell technologies offer powerful approaches to explore heterogeneity within seemingly uniform cell populations. For antibody research, single-cell analysis can:

• Reveal rare subpopulations with distinct antigenic profiles

• Track temporal changes in antigen expression during cellular differentiation or drug response

• Correlate antigen expression with functional phenotypes at the single-cell level

When applying single-cell approaches to drug resistance studies similar to those investigating ara-C-resistant leukemic cells, researchers might uncover subpopulations with varying degrees of resistance and corresponding antigen expression patterns . Technologies like CyTOF (mass cytometry), single-cell RNA-seq paired with protein detection (CITE-seq), and high-dimensional flow cytometry would be particularly valuable for such investigations.

What emerging technologies might enhance antibody engineering for multi-specificity?

Recent advances in antibody engineering extend beyond traditional affinity maturation approaches:

The success of engineering antibody 496.g3 (bimekizumab) to effectively neutralize both IL-17A and IL-17F demonstrates the potential of targeted engineering approaches . Future efforts might employ machine learning algorithms trained on existing antibody-antigen structural data to predict mutations likely to enhance cross-reactivity while maintaining primary target affinity. When selecting engineering approaches, researchers should consider not only binding affinity but also structural stability, expression yield, and manufacturing compatibility.